vs

Side-by-side financial comparison of Brookfield Business Corp (BBUC) and ResMed (RMD). Click either name above to swap in a different company.

Brookfield Business Corp is the larger business by last-quarter revenue ($1.9B vs $1.4B, roughly 1.3× ResMed). ResMed runs the higher net margin — 27.6% vs -1.2%, a 28.8% gap on every dollar of revenue. On growth, ResMed posted the faster year-over-year revenue change (11.0% vs -3.6%).

Brookfield Business Partners L.P. is a publicly traded limited partnership and the primary public vehicle through which Brookfield Corporation, its parent company, owns and operates the business services and industrial operations of its private equity group. It was formed through a spin-off from Brookfield Asset Management in June 2016.

ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.

BBUC vs RMD — Head-to-Head

Bigger by revenue
BBUC
BBUC
1.3× larger
BBUC
$1.9B
$1.4B
RMD
Growing faster (revenue YoY)
RMD
RMD
+14.6% gap
RMD
11.0%
-3.6%
BBUC
Higher net margin
RMD
RMD
28.8% more per $
RMD
27.6%
-1.2%
BBUC

Income Statement — Q2 FY2025 vs Q4 FY2026

Metric
BBUC
BBUC
RMD
RMD
Revenue
$1.9B
$1.4B
Net Profit
$-23.0M
$392.6M
Gross Margin
61.8%
Operating Margin
34.6%
Net Margin
-1.2%
27.6%
Revenue YoY
-3.6%
11.0%
Net Profit YoY
-157.5%
13.9%
EPS (diluted)
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBUC
BBUC
RMD
RMD
Q2 26
$1.4B
Q4 25
$1.4B
Q3 25
$1.3B
Q2 25
$1.9B
$1.3B
Q1 25
$1.3B
Q4 24
$1.3B
Q3 24
$1.2B
Q2 24
$1.9B
$1.2B
Net Profit
BBUC
BBUC
RMD
RMD
Q2 26
$392.6M
Q4 25
$392.6M
Q3 25
$348.5M
Q2 25
$-23.0M
$379.7M
Q1 25
$365.0M
Q4 24
$344.6M
Q3 24
$311.4M
Q2 24
$40.0M
$292.2M
Gross Margin
BBUC
BBUC
RMD
RMD
Q2 26
61.8%
Q4 25
61.8%
Q3 25
61.5%
Q2 25
60.8%
Q1 25
59.3%
Q4 24
58.6%
Q3 24
58.6%
Q2 24
58.5%
Operating Margin
BBUC
BBUC
RMD
RMD
Q2 26
34.6%
Q4 25
34.6%
Q3 25
33.4%
Q2 25
33.7%
Q1 25
33.0%
Q4 24
32.5%
Q3 24
31.6%
Q2 24
31.2%
Net Margin
BBUC
BBUC
RMD
RMD
Q2 26
27.6%
Q4 25
27.6%
Q3 25
26.1%
Q2 25
-1.2%
28.2%
Q1 25
28.3%
Q4 24
26.9%
Q3 24
25.4%
Q2 24
2.1%
23.9%
EPS (diluted)
BBUC
BBUC
RMD
RMD
Q2 26
$2.68
Q4 25
$2.68
Q3 25
$2.37
Q2 25
$2.58
Q1 25
$2.48
Q4 24
$2.34
Q3 24
$2.11
Q2 24
$1.97

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBUC
BBUC
RMD
RMD
Cash + ST InvestmentsLiquidity on hand
$613.0M
$1.4B
Total DebtLower is stronger
$663.8M
Stockholders' EquityBook value
$2.6B
$6.3B
Total Assets
$16.3B
$8.5B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBUC
BBUC
RMD
RMD
Q2 26
$1.4B
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$613.0M
$1.2B
Q1 25
$932.7M
Q4 24
$521.9M
Q3 24
$426.4M
Q2 24
$754.0M
$238.4M
Total Debt
BBUC
BBUC
RMD
RMD
Q2 26
$663.8M
Q4 25
$403.9M
Q3 25
$408.7M
Q2 25
$658.4M
Q1 25
$663.1M
Q4 24
$662.9M
Q3 24
$667.6M
Q2 24
$697.3M
Stockholders' Equity
BBUC
BBUC
RMD
RMD
Q2 26
$6.3B
Q4 25
$6.3B
Q3 25
$6.1B
Q2 25
$2.6B
$6.0B
Q1 25
$5.5B
Q4 24
$5.3B
Q3 24
$5.2B
Q2 24
$4.6B
$4.9B
Total Assets
BBUC
BBUC
RMD
RMD
Q2 26
$8.5B
Q4 25
$8.5B
Q3 25
$8.3B
Q2 25
$16.3B
$8.2B
Q1 25
$7.6B
Q4 24
$7.1B
Q3 24
$7.2B
Q2 24
$20.5B
$6.9B
Debt / Equity
BBUC
BBUC
RMD
RMD
Q2 26
0.11×
Q4 25
0.06×
Q3 25
0.07×
Q2 25
0.11×
Q1 25
0.12×
Q4 24
0.13×
Q3 24
0.13×
Q2 24
0.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons